Antibody-drug conjugate

Uncategorized

Pegram Excited for Additional Advances in HER2+ Breast Cancer

By:The Tutu Team | 31st October 2016

Mark Pegram, MD Though some clinicians may characterize the treatment landscape of HER2-positive...